Rabies Clinical Trial
Official title:
Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in Pre-exposure Use in Healthy Adults
The aim of this study is to generate data on immunogenicity and safety of Purified Vero
Rabies Vaccine - Serum Free (VRVg) in comparison with Imovax® Rabies in order to support the
registration of VRVg in the USA.
Primary Objectives:
- To demonstrate that VRVg is non inferior to Imovax® Rabies in terms of proportion of
subjects achieving an rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL at Day
42.
- To demonstrate that the observed proportion of subjects achieving an RVNA titer ≥ 0.5
IU/mL at Day 42 is at least 99%, with a 95% lower confidence limit of at least 97%.
Secondary Objectives:
- To assess the clinical safety of VRVg each vaccine after each vaccine injection when
administered in a pre-exposure schedule.
- To describe the immune response induced by each vaccine 21 days after two vaccinations
(Day 28) in a randomized subset of subjects and 14 days after the last vaccination of
the primary vaccination series.
- To describe antibody persistence at 6 and 12 months after the first vaccination in all
subjects, and at 18 and 24 months in a subset of subjects.
The vaccination will be given in three injections, at Day 0, Day 7, and Day 28, respectively,
based on the Advisory Committee on Immunization Practice (ACIP) and the World Health
Organization (WHO) recommendations for pre-exposure regimen. A booster dose will be
administered 1 year after the first vaccine injection in a randomized subset of participants.
Safety will be assessed in all participants up to 28 days after vaccination, as applicable,
in terms of occurrence of adverse events (AEs), and serious adverse events (SAEs) and adverse
events of special interest (AESIs) up to Month 12.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03961555 -
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
|
Phase 2 | |
| Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
| Active, not recruiting |
NCT05667974 -
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
|
Phase 3 | |
| Completed |
NCT01641315 -
Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
|
N/A | |
| Completed |
NCT02238756 -
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01930357 -
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
|
Phase 2 | |
| Completed |
NCT01680016 -
A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
|
Phase 3 | |
| Completed |
NCT04019444 -
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02729168 -
Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly
|
N/A | |
| Completed |
NCT02241135 -
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01388985 -
Simplifying the Rabies Pre-exposure Vaccination
|
Phase 3 | |
| Completed |
NCT04829630 -
Immunity Persistence After Abridged Intradermal Rabies PEP
|
N/A | |
| Completed |
NCT03713086 -
A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT05350735 -
Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project
|
N/A | |
| Active, not recruiting |
NCT06132789 -
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years
|
Phase 1 | |
| Completed |
NCT02281396 -
The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
|
Phase 1 | |
| Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
| Completed |
NCT00825305 -
Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)
|
Phase 3 | |
| Completed |
NCT05547815 -
Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
|
Phase 4 | |
| Completed |
NCT02564471 -
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
|
Phase 4 |